`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`ACCORD HEALTHCARE, INC., USA
`Petitioner
`
`V.
`
`ELI LILLY & COMPANY,
`
`Patent Owner
`
`Case IPR2013-00356
`
`US. Patent No. 7,772,209
`
`MANDATORY NOTICE INFORMATION
`
`PURSUANT TO 37 C.F.R. § 42.8
`
`Pursuant to 37 C.F.R. § 42.8(a)(2), Patent Owner Eli Lilly and Company
`
`submits the following mandatory notice information.
`
`
`
`Case IPR2013-00356
`
`US. Patent No. 7,772,209
`
`Docket No.
`
`X14173BIPR
`
`REAL PARTY—IN—INTEREST
`
`Eli Lilly and Company, a publicly traded company, is a corporation
`
`organized and existing under the laws of the State of Indiana with its corporate
`
`offices and principal place of business at Lilly Corporate Center, Indianapolis,
`
`Indiana 46285. Eli Lilly and Company is the owner of the entire interest in US.
`
`Patent 7,772,209 (the “’209 patent”).
`
`
`
`Case IPR2013-00356
`
`US. Patent No. 7,772,209
`
`Docket No.
`
`X14173BIPR
`
`RELATED MATTERS
`
`The following matters could affect, or be affected by, a decision in this
`
`proceeding:
`
`0 The ’209 patent has been asserted in the following litigations consolidated
`
`under Civil Action No. lle-cv-01376-TWP—DKL, which is currently
`
`pending in the US. District Court for the Southern District of Indiana:
`
`0 Eli Lilly & Co. v. Teva Parenteral Medicines, Inc, APP
`
`Pharmaceuticals, LLC, Pliva Hrvatska D. 0. 0., Teva Pharmaceuticals
`
`USA Inc, and Barr Laboratories, Inc, Civil Action No. l:lO—cv-
`
`01376-TWP-DKL (S.D. Ind); and
`
`0 Eli Lilly & Co. v. APP Pharmaceuticals, LLC, Civil Action No. 1:1 1—
`
`cv-OO942-TWP-TAB (S.D. Ind.).
`
`o The ’209 patent has also been asserted in the following litigations
`
`consolidated under Civil Action No. 1:12-cv-00086—TWP-DKL, which is
`
`currently pending in the US. District Court for the Southern District of
`
`Indiana:
`
`0 Eli Lilly & Co. v. Accord Healthcare Inc, USA, Apotex Inc, and
`
`Apotex Corp, Civil Action No. 1:12-cv—00086-TWP-DKL (S.D.
`
`Ind.);
`
`
`
`Case IPR2013-003 56
`US. Patent No. 7,772,209
`
`Docket No.
`X14173BIPR
`
`0 Eli Lilly & Co. v. Apotex Inc. and Apotex Corp, Civil Action No.
`
`1:12-cv-00499—TWP-DKL (SD. Ind); and
`
`0 Eli Lilly & Co. v. Accord Healthcare Inc, USA, Civil Action No.
`
`1:13—cv-OO335-TWP—DKL (SD. Ind.).
`
`
`
`Case IPR2013-00356
`US. Patent No. 7,772,209
`
`Docket No.
`X14 1 73BIPR
`
`LEAD AND BACK-UP COUNSEL
`
`Patent Owner Eli Lilly and Company designates the following lead and
`
`back-up counsel:
`
`Lead Counsel
`
`Back-Up Counsel
`
`Andrew V. Trask
`
`Mark J. Stewart
`
`Reg. No. 59,239
`
`Reg. No. 43,936
`
`Williams & Connolly LLP
`
`Eli Lilly and Company
`
`725 Twelfth Street, NW.
`
`Lilly Corporate Center
`
`Washington, DC 20005
`
`Indianapolis, IN 46285
`
`202—434-5098 (Telephone)
`
`317—276—0280 (Telephone)
`
`202-824-4223 (Facsimile)
`
`317-276—3861 (Facsimile)
`
`atrask@wc.com
`
`Stewart_Mark@Lilly.com
`
`A power of attorney appointing Andrew V. Trask to transact all business in
`
`this proceeding is submitted together with this mandatory notice information.
`
`Mark J. Stewart is already counsel of record with regard to the ’209 patent. See 37
`
`CPR. § 42.10(b).
`
`
`
`Case IPR2013-00356
`
`US. Patent No. 7,772,209
`
`Docket No.
`
`X14173BIPR
`
`SERVICE INFORMATION
`
`Patent Owner Eli Lilly and Company submits the following service
`
`information for itself:
`
`(i)
`
`Electronic mail addresses:
`
`atrask@wc.com
`
`Stewart_Mark@Lilly.com
`
`patents@lilly.com
`
`(ii)
`
`Postal mailing address:
`
`Andrew V. Trask
`
`Williams & Connolly LLP
`
`725 Twelfth Street, NW.
`
`Washington, DC 20005
`
`(iii) Hand-delivery address:
`
`Andrew V. Trask
`
`Williams & Connolly LLP
`
`725 Twelfth Street, NW.
`
`Washington, DC 20005
`
`(iv) Telephone number:
`
`202—434-5098
`
`(v)
`
`Facsimile number:
`
`202—824—4223
`
`Patent Owner Eli Lilly and Company consents to electronic service by email
`
`at: atrask@wc.com, Stewart_Mark@Lilly.com, and patents@lilly.com.
`
`
`
`Case IPR2013—00356
`
`US. Patent No. 7,772,209
`
`Docket No.
`
`X14173BIPR
`
`CONCLUSION
`
`Patent Owner Eli Lilly and Company believes this submission fulfills the
`
`requirements of 37 C.F.R. § 42.8. If any additional information is required, please
`
`contact the undersigned counsel at the address shown below.
`
`The Commissioner is hereby authorized to charge any fees or costs
`
`associated with this submission and to credit any excess payments to Deposit
`
`Account No. 05—0840.
`
`Dated: July 1, 2013
`
`Respectfully submitted,
`
`An ew V. Trask
`
`Reg. No. 59,239
`Williams & Connolly LLP
`725 Twelfth Street, NW.
`
`Washington, DC 20005
`202-434-5098 (Telephone)
`202—824-4223 (Facsimile)
`atrask@wc.com
`
`Attorney for Patent Owner
`Eli Lilly and Company
`
`
`
`Case IPR2013—00356
`
`US. Patent No. 7,772,209
`
`Docket No.
`
`X14173BIPR
`
`CERTIFICATE OF SERVICE
`
`The undersigned hereby certifies that the foregoing Mandatory Notice
`Information Pursuant to 37 C.F.R. § 42.8(a)(2) was served on July 1, 2013, by
`filing this document through the Patent Review Processing System as well as
`delivering a copy via electronic mail upon the following attorneys of record for the
`Petitioner:
`
`Chidambaram S. Iyer
`ciyer@sughrue.com
`Sughrue Mion PLLC
`2100 Pennsylvania Ave, NW
`Washington, DC 20037
`
`Chandran B. Iyer
`cbier@sughrue.corn
`Sughrue Mion PLLC
`2100 Pennsylvania Ave, NW
`Washington, DC 20037
`
`Dated: July 1, 2013
`
`Respectfully submitted,
`
`An ew V. Trask
`
`